Navigation Links
DiObex, Inc. Awarded Patent for the Prevention of Insulin-Induced Hypoglycemia

Patent Protects Very Low Dose Glucagon ahead of Phase 2 Clinical Trials in


SAN FRANCISCO, Jan. 8 /PRNewswire/ -- DiObex, Inc., a privately held biotechnology company developing treatments for metabolic diseases, announced today that it has secured a critical patent from the U.S. Patent and Trademark Office for the use of very low dose glucagon, or DIO-901, in the prevention of insulin-induced hypoglycemia in diabetes patients. The patent grants DiObex exclusive rights to methods of reducing the risk of hypoglycemia in diabetes patients being treated with insulin by administering very low doses of glucagon.

"This patent protection strengthens our commitment to delivering the first product to the market for the prevention of insulin-induced hypoglycemia in diabetes," CEO David Cory said. "DIO-901 is the only therapeutic in development to prevent insulin-induced hypoglycemia, which is known to limit optimal glycemic control and cause recurring medical complications in most people with type 1 diabetes, in many with type 2 diabetes, and is sometimes fatal."

Insulin-induced hypoglycemia is the limiting factor in the glycemic management of diabetes. Were it not for the barrier of hypoglycemia, people with diabetes might achieve normal HbA1c levels over a lifetime of diabetes. Reduction of mean glycemia over time prevents or delays microvascular complications -- retinopathy, nephropathy, and neuropathy -- in both type 1 and type 2 diabetes. DIO-901 is expected to begin Phase 2 clinical testing later this year and has received Fast Track status from the Food and Drug Administration, underscoring the great unmet medical need in the prevention of insulin-induced hypoglycemia.

DiObex's latest patent, U.S. Patent No. 7,314,859, builds on a growing patent portfolio protecting its product candidates for metabolic diseases. In addition to the recently issued U.S. patent, DiObex owns seven U.S. patent applications and 30 corresponding foreign patent applications relating to DIO-901. DiObex also owns or has exclusively licensed seven U.S. patents, five U.S. patent applications, and more than 100 issued foreign patents and pending foreign and international patent applications relating to DIO-902.

About DiObex

DiObex, Inc. is a privately held San Francisco-based biotechnology company developing novel products for diabetes and metabolic diseases. DiObex has two product candidates in four mid-stage clinical development programs. DIO-901 (very low dose glucagon) is in development for the prevention of insulin-induced hypoglycemia in type 1 diabetes mellitus in an extended release subcutaneous formulation and as a convenient continuous subcutaneous infusion. DIO-901 has received Fast Track status from the FDA. DIO-902 (levdexketoconazole) is an oral, single enantiomer of ketoconazole that is a novel cortisol synthesis inhibitor in development for type 2 diabetes mellitus and diabetic nephropathy. Abnormalities in cortisol activity may play an important role in the development of metabolic syndrome, a constellation of conditions that place people at high risk for type 2 diabetes mellitus and cardiovascular disease. For more information, visit

SOURCE DiObex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Congressional Funds Awarded for Testing of Antimicrobial Copper Metals
2. SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases
3. National Jewish, Brigham and Womens Awarded $37 Million to Identify Genes and Other Risk Factors that Influence the Development of COPD
4. Nobel Prize Awarded to Foundation for Biomedical Research Board Member
5. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
6. Federal Funding Awarded to Test Antimicrobial Properties of Copper Metals
7. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
8. Xenomics Announces Issuance of a US Patent That Covers Use of Transrenal Nucleic Acid Technology for Infectious Disease Diagnostics and Monitoring
9. Consumer Advocates Support Patent Office on Stem Cell Patent Rejection
10. AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer
11. Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
Post Your Comments:
(Date:12/1/2015)... -- CytRx Corporation (NASDAQ: CYTR ), a biopharmaceutical ... that it has reached its enrollment target of 400 ... trial of aldoxorubicin in patients with previously treated soft ... in Q1 2016. The Phase 3 trial is a randomized, ... from the FDA at 79 sites in ...
(Date:12/1/2015)... Dec. 1, 2015  InCarda Therapeutics, Inc. (InCarda), a ... of therapies for cardiovascular conditions via the inhalation route, ... in Australia . InCarda is planning ... Australia in the first half of ... medical centers in Adelaide and ...
(Date:12/1/2015)... , Dec. 1, 2015  Booth #3506 – Claymount is ... the annual meeting of the Radiological Society of ... this year. Based in the Netherlands ... Varian Medical Systems (NYSE: VAR ) and is one ... chambers and solid state automatic exposure control systems for controlling ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... ... continuing medical education (CME), today announced that the first annual School of Gastrointestinal ... , “The prevention, detection and treatment of gastrointestinal cancers are undergoing transformational change, ...
(Date:12/1/2015)... ... 01, 2015 , ... Speech and physical therapies are traditionally ... technologies and under the right circumstances, these practices can be merged. This ... to his or her therapeutic sessions, as well as gives the physical and ...
(Date:12/1/2015)... ... December 01, 2015 , ... CloudLIMS ... 2015 Golden Bridge Business Awards under the New Products and Services category for ... based sample management software that helps labs organize data and track ...
(Date:12/1/2015)... CHICAGO (PRWEB) , ... December 01, 2015 , ... ... risk quantification and optimization of adjunctive imaging is the focus of numerous abstracts ... (RSNA) meeting, November 29-December 4, 2015. Nine abstracts highlight the use of ...
(Date:12/1/2015)... ... 01, 2015 , ... SAN FRANCISCO, Calif. (December 1, 2015) ... has awarded Education and Developmental Therapies (EDT), an Applied Behavior Analysis (ABA) service ... special needs providers that excel in synthesizing the areas of clinical quality, staff ...
Breaking Medicine News(10 mins):